251 related articles for article (PubMed ID: 27806001)
1. OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.
Chin EK; Almeida DRP; Velez G; Xu K; Peraire M; Corbella M; Elshatory YM; Kwon YH; Gehrs KM; Boldt HC; Sohn EH; Russell SR; Folk JC; Mahajan VB
Retina; 2017 Jul; 37(7):1345-1351. PubMed ID: 27806001
[TBL] [Abstract][Full Text] [Related]
2. SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension.
Malclès A; Dot C; Voirin N; Vié AL; Agard É; Bellocq D; Denis P; Kodjikian L
Retina; 2017 Jul; 37(7):1352-1359. PubMed ID: 27768641
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex®) on intraocular pressure in patients with macular edema.
Mazzarella S; Mateo C; Freixes S; Burés-Jelstrup A; Rios J; Navarro R; García-Arumí J; Corcóstegui B; Arrondo E
Ophthalmic Res; 2015; 54(3):143-9. PubMed ID: 26394206
[TBL] [Abstract][Full Text] [Related]
4. LONG-TERM INCIDENCE AND RISK FACTORS OF OCULAR HYPERTENSION FOLLOWING DEXAMETHASONE-IMPLANT INJECTIONS: THE SAFODEX-2 STUDY.
Rezkallah A; Mathis T; Abukhashabah A; Voirin N; Malclès A; Agard É; Lereuil T; Denis P; Dot C; Kodjikian L
Retina; 2021 Jul; 41(7):1438-1445. PubMed ID: 33315814
[TBL] [Abstract][Full Text] [Related]
5. Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension.
Theodoropoulou S; Ellabban AA; Johnston RL; Cilliers H; Mohamed Q; Sallam AB
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):725-732. PubMed ID: 27878430
[TBL] [Abstract][Full Text] [Related]
6. Ocular hypertension management in long-term treatments with intravitreal dexamethasone implants: a 3-year experience.
Monsellato R; Trovato E; Turchetti P; Forestiere M; Pistone A; De Sio S; Accetta L; Pacella F
Clin Ter; 2020; 170(1):e11-e14. PubMed ID: 31850478
[TBL] [Abstract][Full Text] [Related]
7. Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients.
Choi W; Park SE; Kang HG; Byeon SH; Kim SS; Koh HJ; Lee S; Seong GJ; Kim CY; Kim M
Br J Ophthalmol; 2019 Oct; 103(10):1380-1387. PubMed ID: 30523044
[TBL] [Abstract][Full Text] [Related]
8. INTRAOCULAR DEXAMETHASONE IMPLANT POSITION IN SITU AND OCULAR HYPERTENSION.
Sudhalkar A; Kodjikian L; Chhablani J; Bhojwani D; Vasavada A
Retina; 2018 Dec; 38(12):2343-2349. PubMed ID: 29016454
[TBL] [Abstract][Full Text] [Related]
9. [Effects of ozurdex on intraocular pressure. A real life clinical practice study].
Jiménez-Gómez B; González-Montpetit M; Fonollosa Calduch A; Orive Bañuelos A; Valsero Franco S
Arch Soc Esp Oftalmol; 2015 Sep; 90(9):421-5. PubMed ID: 25817950
[TBL] [Abstract][Full Text] [Related]
10. Intraocular pressure fluctuation following intravitreal dexamethasone implant and incidence of secondary ocular hypertension: a Zambian perspective.
Raj P; Kumar K; Balasubramaniam S; Geetha CS; Agarwal A
Pan Afr Med J; 2021; 39():108. PubMed ID: 34512844
[TBL] [Abstract][Full Text] [Related]
11. Secondary Ocular Hypertension and the Risk of Glaucoma Surgery After Dexamethasone Intravitreal Implant in Routine Clinical Practice.
Hemarat K; Kemmer JD; Porco TC; Eaton AM; Khurana RN; Stewart JM
Ophthalmic Surg Lasers Imaging Retina; 2018 Sep; 49(9):680-685. PubMed ID: 30222802
[TBL] [Abstract][Full Text] [Related]
12. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
[TBL] [Abstract][Full Text] [Related]
13. OBSERVED COMPLICATIONS FROM DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA IN RETINAL VEIN OCCLUSION OVER 3 TREATMENT ROUNDS.
Reid GA; Sahota DS; Sarhan M
Retina; 2015 Aug; 35(8):1647-55. PubMed ID: 25932545
[TBL] [Abstract][Full Text] [Related]
14. Ocular hypertension and its predictor after a single Ozurdex implant: One-year follow-up in Asian Indian eyes.
Mansoori T; Shiva S; Balakrishna N
Oman J Ophthalmol; 2022; 15(3):299-303. PubMed ID: 36760962
[TBL] [Abstract][Full Text] [Related]
15. Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant.
Pérez-Sarriegui A; Casas-Llera P; Díez-Álvarez L; Contreras I; Moreno-López M; Figueroa MS; González-Martín-Moro J; Muñoz-Negrete FJ; Rebolleda G
Arch Soc Esp Oftalmol (Engl Ed); 2018 Dec; 93(12):580-585. PubMed ID: 30266279
[TBL] [Abstract][Full Text] [Related]
16. Ocular Hypertension Following Intravitreal Injection of 0.7mg Dexamethasone Implant versus 2mg Triamcinolone.
Kuley B; Storey PP; Pancholy M; Obeid A; Murphy J; Goodman J; Wibbelsman TD; Regillo C; Chiang A
Semin Ophthalmol; 2020 Feb; 35(2):141-146. PubMed ID: 32343619
[No Abstract] [Full Text] [Related]
17. Surgical intervention of steroid-induced ocular hypertension from Ozurdex.
Sejpal P; Scott-Weideman J
Optom Vis Sci; 2013 Jan; 90(1):e24-30. PubMed ID: 23241827
[TBL] [Abstract][Full Text] [Related]
18. [Reliability and safety of intravitreal Ozurdex injections. The ZERO study].
Schmitz K; Maier M; Clemens CR; Höhn F; Wachtlin J; Lehmann F; Bertelmann T; Rüdiger K; Horn M; Bezatis A; Spital G; Meyer CH;
Ophthalmologe; 2014 Jan; 111(1):44-52. PubMed ID: 23559321
[TBL] [Abstract][Full Text] [Related]
19. [Tolerability and short-term efficacy of the Ozurdex® dexamethasone intravitreal implant for treatment of uveitic cystoid macular edema: A retrospective study of 52 injections performed at the Clermont-Ferrand teaching hospital].
Bernard Y; Bonnin N; Farguette F; Chiambaretta F
J Fr Ophtalmol; 2016 Jan; 39(1):1-4. PubMed ID: 26616298
[TBL] [Abstract][Full Text] [Related]
20. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
Adelman RA; Zheng Q; Mayer HR
J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
